Partner Article
Israeli arthritis treatment business to bring jobs to North East
An Israeli medical firm which is pioneering a non-invasive form of therapy for knee and back pain has announced plans to set up shop in the North East within the next two years.
AposTherapy, which operates offices in Israel, New York, London and Singapore, says it intends to open branches in Bristol and the North East.
The £10 million investment will create hundreds of UK jobs over the next three years and will add to AposTherapy’s presence in Manchester, Birmingham, Ken and Sussex.
AposTherapy’s technique uses a foot-worn biomechanical device which is individually-calibrated for the user.
The announcement was made as part of David Cameron’s current visit to Israel and Palestine, where he is joined by Trade and Investment Minister Lord Livingston.
A further £50 million has been committed by Israel’s Noy Infrastructure and Engery Investment Fund to the UK’s renewable energy sector, and £12 million from pharma company Teva will go towards clinical development in the UK.
Lord Livingston said: “These announcements are testament to how the UK and Israel work successfully together. UK exports have grown steadily and we are now the third largest exporter to Israel and there are now over 250 Israeli companies operating in the UK.
“There is huge potential to increase trade and investment with Israel and the Palestinian Territories. I look forward to building on this success with the work of UKTI.”
This was posted in Bdaily's Members' News section by Tom Keighley .
Enjoy the read? Get Bdaily delivered.
Sign up to receive our daily bulletin, sent to your inbox, for free.
Time to end London monopoly on arts talent
Why local government is key to devolution success
Your reputation is worth more than that invoice
There is no perfect time when selling a business
What next when social media career help goes?
The psychological contract that nobody signs
Time for strategy built on the foundational economy
Why being ‘work-ready’ matters more than ever
The North's future doesn't end at Manchester
Exit or legacy? Why every owner needs a plan
Who speaks up for SMEs when giants get bigger?
The true value of HR in an AI-driven working world